Description
Cagrisema 10mg is a combination research compound consisting of Cagrilintide (an amylin receptor analog) and Semaglutide (a GLP-1 receptor analog), studied in preclinical and clinical research for their interactions with peptide receptor binding and neuroendocrine signaling pathway analysis. Available exclusively for licensed research and laboratory use.
Research Background
This compound combination has been investigated in peer-reviewed studies examining dual receptor activation and associated endocrine signaling mechanisms. References are provided for informational purposes relating to published scientific literature.
Product Specifications
- Composition: Cagrilintide + Semaglutide combination, 10mg total
- Purity: 99%+ verified by LCMS
- Format: Lyophilized powder
- Storage: -20°C, protected from light
For research use only. Not for human or animal consumption. Not a drug, food, or cosmetic. Must be handled by licensed, qualified professionals in a controlled laboratory setting.
Research Resources
For research purposes only. Not for human use.












